Feb 4, 2026
Here at XBiotech, we're pleased to share a significant publication recently released in the Journal of Microscopy (DOI: 10.1111/jmi.70038), which highlights our ongoing collaboration with UT Austin to advance our infectious disease pipeline through refined imaging techniques.
This steady progress complements our broader efforts, as our Research and Development team maintains a clear focus on key infectious disease areas such as shingles, C. difficile, influenza, S. aureus, and JC virus infections, while our Manufacturing and Clinical teams continue their work in oncology and rheumatology as we progress into 2026.
Modern medicine should help patients feel better, not worse. At XBiotech, we believe in the Hippocratic principle of "do no harm." We believe this is inherent to the innovative True Human™ antibody medicines we are developing. True Human™ antibodies move beyond the idea that effective medicines must come with toxicity or harmful side effects.
By utilizing the body’s natural immune system, XBiotech develops therapies that help you heal and feel better.